LONDON, UK / ACCESSWIRE / July 23, 2018 / If you want access to our free research report on Allergan PLC (NYSE: AGN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AGN as the Company's latest news hit the wire. On July 19, 2018, the Company and Molecular Partners AG together announced positive results from two clinical trials, SEQUOIA and CEDAR, evaluating the efficacy and safety of abicipar compared to ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration (AMD). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Allergan most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AGN

Both Trials Met Primary Endpoint of Percentage of Patients with Stable Vision at Week 52

The trials demonstrated that abicipar at both the 8-week and 12-week treatment regimens met the pre-specified primary endpoint of non-inferiority compared to ranibizumab. The primary endpoint measured the proportion of treated patients with stable vision at week 52. In both studies, abicipar demonstrated similar efficacy after 6 or 8 injections compared to 13 ranibizumab injections in the first year of this study. The overall adverse events were similar among the three treatment arms, although the incidence of intraocular inflammation was higher in the abicipar arms compared to ranibizumab-treated patients in both trials. These results are being further analyzed. The SEQUOIA and CEDAR clinical trials will continue on a masked basis for a second year.

The regulatory filing for abicipar is planned for the first half of 2019. Allergan will be requesting a meeting with the US Food and Drug Administration (FDA) to discuss the BLA submission. The full data details of the primary and secondary endpoints will be presented at an upcoming scientific conference.

Allergan will Continue to Work on Further Optimizing the Abicipar Formulation

David Nicholson, Chief Research and Development Officer of Allergan, stated that the Company is pleased with the outcome of these trials. The SEQUOIA and CEDAR studies demonstrated what Allergan set out to achieve strong efficacy and duration of effect which shows the potential of abicipar as a treatment for AMD patients. Nicholson added that the Company will continue to review these data, including inflammation findings, and it is working on further optimizing the abicipar formulation.

About Abicipar

Abicipar is a long-acting mono-DARPin® drug candidate that inhibits vascular endothelial growth factor A (VEGF-A); and is currently under investigation for the treatment of two major causes of blindness worldwide, which are wet AMD and diabetic macular edema (DME). Abicipar has the potential to require less frequent injections into the eye than the current anti-VEGF standards of care, while providing equal or better improvements in vision, both seen as major patient benefits in these indications. Molecular Partners granted an exclusive license to Allergan for abicipar in May 2011.

About Age-Related Macular Degeneration (AMD)

AMD is a disease that causes the gradual loss of sight due to blurring or loss of central vision. This is often a result of a deterioration of the macula, which is a yellow pigmented structure at the back of the eye that is responsible for one's detailed color vision. AMD is a chronic disease; it cannot be cured, and in many patients sight cannot be restored after it is lost. However certain forms of the disease can be treated. Early detection is important to potentially stop the spread of the disease and to protect the sight.

About Allergan PLC

Headquartered in Dublin, Ireland, Allergan is a global pharmaceutical organization focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products for patients around the world.

About Molecular Partners AG

Headquartered in Zurich, Switzerland, Molecular Partners is a clinical-stage biopharmaceutical Company working to advance modern medicine and significantly improve the management of serious diseases. The Company is currently developing a powerful new class of potent, specific, and versatile small protein therapies called DARPin® therapeutics.

Stock Performance Snapshot

July 20, 2018 - At Friday's closing bell, Allergan's stock was slightly down 0.92%, ending the trading session at $171.79.

Volume traded for the day: 1.50 million shares.

Stock performance in the previous three-month period ? up 8.38%; and year-to-date - up 5.02%

After last Friday's close, Allergan's market cap was at $59.63 billion.

The stock has a dividend yield of 1.68%.

The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors